Literature DB >> 31951506

Prospective Cohort Study on Timing of Antimicrobial Prophylaxis for Post-Cesarean Surgical Site Infections.

Angie Sway1, Anthony Wanyoro2, Peter Nthumba3, Alexander Aiken4, Patrick Ching5, Anna Maruta6, Revathi Gunturu7, Joseph Solomkin8.   

Abstract

Background: Sepsis is the leading cause of maternal death in sub-Saharan Africa (SSA), a region that sees some of the highest rates of maternal death and morbidity in the world. As one of the most commonly performed surgical procedures in SSA and a proved risk factor for surgical site infection (SSI), cesarean section (CS) is an important operation to target because of its massive impact on maternal and neonatal health. There is currently insufficient published data available on the patient and facility-based context around SSI after CS to establish a true and clear understanding of this infectious category. The objective of this study was to collect accurate and valid data on the incidence of SSI after CS and the circumstances around SSI in two Kenyan hospitals. Hypothesis: Our primary analysis focused on the consequences of timing of peri-operative antimicrobial prophylaxis. We hypothesized that patients who were given antibiotics pre-operatively would show lower SSI rates than those given the agents post-operatively.
Methods: This was an Institutional Review Board-approved observational study of 609 women who had CS operations at two Kenyan hospitals from September to December 2015. Thika provided antimicrobial prophylaxis prior to incision for all patients, and Kiambu provided only post-operative prophylaxis. It should be noted that this difference was the result of a previous intervention at Thika and not a part of this observational study.
Results: Patients at the two hospitals had similar pre-operative characteristics indicating a relatively healthy population. The median age was 26 ± 6 years (range 18-43) at Thika and 26 ± 5 (18-44) at Kiambu. Median parity was 1 ± 1 (range 0-7) at Thika and 1 ± 1 (0-10). Patients also went through a comparable number of antenatal care visits (median 4 ± 1 at both hospitals). The number of patients with prolonged rupture of the membranes was 103 (34.4%) at Thika and 99 (32.9%) at Kiambu. There was a slightly higher number of patients with meconium-stained liquor at Kiambu Hospital (115) than at Thika (74). The SSI rate was 4.0% (12/299; 11 superficial, 1 deep) at Thika and 9.3% (28/301; 18 superficial, 7 deep, 3 organ/space) at Kiambu. Conclusions: The data show a striking difference between SSI rates in patients who were given properly timed pre-operative antibiotics and patients who were given only post-operative antibiotics. Administration of post-operative antibiotics is currently the norm in much of SSA, and there is strong evidence that many of the infectious problems encountered in this population would be reduced by the provision of antibiotic prophylaxis prior to the incision.

Entities:  

Keywords:  cesarean section/cesarean delivery; global surgery; pre-operative prophylaxis; sepsis; surgical site infection

Mesh:

Substances:

Year:  2020        PMID: 31951506     DOI: 10.1089/sur.2018.226

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  2 in total

1.  Antibiotic Prescribing in Connection to Childbirth: An Observational Study in Two Districts in Lao PDR.

Authors:  Weirong Yan; Anna Machowska; Amphoy Sihavong; Vanphanom Sychareun; Kongmany Chaleunvong; Bounxou Keohavong; Jaran Eriksen; Claudia Hanson; Manivanh Vongsouvath; Annelie Brauner; Mayfong Mayxay; Sengchanh Kounnavong; Cecilia Stålsby Lundborg
Journal:  Antibiotics (Basel)       Date:  2022-03-25

Review 2.  Supporting global antimicrobial stewardship: antibiotic prophylaxis for the prevention of surgical site infection in low- and middle-income countries (LMICs): a scoping review and meta-analysis.

Authors:  Lesley Cooper; Jacqueline Sneddon; Daniel Kwame Afriyie; Israel A Sefah; Amanj Kurdi; Brian Godman; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2020-10-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.